JP2019521156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521156A5 JP2019521156A5 JP2019502063A JP2019502063A JP2019521156A5 JP 2019521156 A5 JP2019521156 A5 JP 2019521156A5 JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019502063 A JP2019502063 A JP 2019502063A JP 2019521156 A5 JP2019521156 A5 JP 2019521156A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- secukinumab
- weeks
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004540 secukinumab Drugs 0.000 claims description 16
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 238000010254 subcutaneous injection Methods 0.000 claims description 10
- 239000007929 subcutaneous injection Substances 0.000 claims description 10
- 239000003124 biologic agent Substances 0.000 claims description 4
- 238000001126 phototherapy Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229940090048 pen injector Drugs 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 108050003558 Interleukin-17 Proteins 0.000 description 15
- 102000013691 Interleukin-17 Human genes 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 9
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022100449A JP2022126791A (ja) | 2016-07-19 | 2022-06-22 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2023172063A JP2024001125A (ja) | 2016-07-19 | 2023-10-03 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2025058479A JP2025102888A (ja) | 2016-07-19 | 2025-03-31 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364007P | 2016-07-19 | 2016-07-19 | |
| US62/364,007 | 2016-07-19 | ||
| PCT/IB2017/054333 WO2018015880A1 (en) | 2016-07-19 | 2017-07-18 | Methods of treating new-onset plaque type psoriasis using il-17 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100449A Division JP2022126791A (ja) | 2016-07-19 | 2022-06-22 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521156A JP2019521156A (ja) | 2019-07-25 |
| JP2019521156A5 true JP2019521156A5 (enExample) | 2020-08-27 |
Family
ID=59677269
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502063A Pending JP2019521156A (ja) | 2016-07-19 | 2017-07-18 | Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2022100449A Withdrawn JP2022126791A (ja) | 2016-07-19 | 2022-06-22 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2023172063A Pending JP2024001125A (ja) | 2016-07-19 | 2023-10-03 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2025058479A Pending JP2025102888A (ja) | 2016-07-19 | 2025-03-31 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100449A Withdrawn JP2022126791A (ja) | 2016-07-19 | 2022-06-22 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2023172063A Pending JP2024001125A (ja) | 2016-07-19 | 2023-10-03 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2025058479A Pending JP2025102888A (ja) | 2016-07-19 | 2025-03-31 | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190194311A1 (enExample) |
| EP (2) | EP4477265A3 (enExample) |
| JP (4) | JP2019521156A (enExample) |
| CN (1) | CN109476733A (enExample) |
| ES (1) | ES2992409T3 (enExample) |
| WO (1) | WO2018015880A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992409T3 (es) * | 2016-07-19 | 2024-12-12 | Novartis Ag | Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17 |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| WO2021018191A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | Il-17拮抗剂治疗自身免疫疾病的方法 |
| EP3797779A1 (en) * | 2019-09-30 | 2021-03-31 | Servei de Salut de Les Illes Balears - Ibsalut | Combined therapy comprising an inhibitor of interleukin-17 activity and a vitamin d receptor agonist |
| AU2020396455A1 (en) * | 2019-12-06 | 2022-06-02 | Novartis Ag | Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists |
| CN113855807A (zh) * | 2021-10-25 | 2021-12-31 | 孙良丹 | 一种试剂在制备治疗/抑制银屑病药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| PL2481753T3 (pl) | 2005-12-13 | 2018-09-28 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| CA2637166A1 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies for treating cancer |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| ES2493042T3 (es) | 2008-09-29 | 2014-09-11 | Roche Glycart Ag | Anticuerpos contra la IL-17 humana y usos de los mismos |
| LT2625199T (lt) * | 2010-10-08 | 2018-03-12 | Novartis Ag | Psoriazės gydymo būdai panaudojant il-17 antagonistus |
| EP2791172B1 (en) | 2011-12-16 | 2017-07-19 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| RS59625B1 (sr) | 2013-02-08 | 2020-01-31 | Novartis Ag | Anti-il-17a antitela i njihova upotreba u lečenju autoimunskih i inflamatornih poremećaja |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP3033107A1 (en) | 2013-08-15 | 2016-06-22 | Novartis AG | Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| ES2992409T3 (es) | 2016-07-19 | 2024-12-12 | Novartis Ag | Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17 |
-
2017
- 2017-07-18 ES ES17754796T patent/ES2992409T3/es active Active
- 2017-07-18 WO PCT/IB2017/054333 patent/WO2018015880A1/en not_active Ceased
- 2017-07-18 US US16/319,174 patent/US20190194311A1/en not_active Abandoned
- 2017-07-18 CN CN201780044280.8A patent/CN109476733A/zh active Pending
- 2017-07-18 JP JP2019502063A patent/JP2019521156A/ja active Pending
- 2017-07-18 EP EP24195418.9A patent/EP4477265A3/en not_active Withdrawn
- 2017-07-18 EP EP17754796.5A patent/EP3487881B1/en active Active
-
2022
- 2022-06-22 JP JP2022100449A patent/JP2022126791A/ja not_active Withdrawn
- 2022-10-07 US US17/938,846 patent/US20230303677A1/en active Pending
-
2023
- 2023-10-03 JP JP2023172063A patent/JP2024001125A/ja active Pending
-
2025
- 2025-03-31 JP JP2025058479A patent/JP2025102888A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521156A5 (enExample) | ||
| CN103458926B (zh) | 改进的高浓度抗TNF α 抗体液体制剂 | |
| CN106062000B (zh) | 通过施用il-4r拮抗剂治疗皮肤感染的方法 | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2008141433A (ru) | Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста | |
| JP2020510039A5 (enExample) | ||
| JP2016505572A5 (enExample) | ||
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2021515003A (ja) | 体組成を変更するための方法 | |
| RU2012108108A (ru) | Концентрированные полипептидные лекарственные формы с пониженной вязкостью | |
| JP2009538916A5 (enExample) | ||
| US20250122270A1 (en) | Intradermal administration of immunoglobulin g preparation | |
| KR20200083996A (ko) | 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법 | |
| JP2005529152A5 (enExample) | ||
| RU2019108441A (ru) | Режим дозирования | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| CA3187136A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists | |
| RU2023102788A (ru) | Лечение гнойного гидраденита с использованием антагонистов il-17 | |
| JPWO2019186369A5 (enExample) | ||
| US20210261656A1 (en) | Compositions and methods for treating autoimmune inner ear disease | |
| RU2020134794A (ru) | Способы лечения хронической спонтанной крапивницы с применением лигелизумаба | |
| JP2020517648A5 (enExample) | ||
| TW202241505A (zh) | 抗il-17抗體治療自體免疫性疾病和炎症的方法 | |
| NZ760588B2 (en) | Methods for Treating TNFa-Related Diseases |